This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "will" and similar terms and phrases may be used to identify forward-looking statements in this presentation. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward- looking statements ultimately prove to be correct.
These forward-looking statements are subject to risks and uncertainties including, among other things, the extent to which the ongoing COVID-19 pandemic continues to disrupt the Company's operations and financial condition and the operations and financial condition of its customers; the Company's ability to manage costs and execute on its operational and budget plans, the Company's ability to achieve its financial goals; the Company's ability to operate under increased leverage and associated lending covenants; to pay its debt under its credit agreement; the Company's ability to maintain relationships, profitability and contracts with commercial partners, including the impact of changes in consumer demand for the products the Company manufactures for its commercial partners; the Company's ability to diversify and grow its business with new customers; customers' changing inventory requirements and manufacturing plans; customer and prospective customers decisions to move forward with our manufacturing services; average profitability, or mix, of the products we manufacture; or customers facing increasing or new competition.
These forward-looking statements should be considered together with the risks and uncertainties that may affect our business and future results included in our filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements except as required by applicable law.
2
Company Highlights
Revenue and cash flow positive contract development and manufacturing (CDMO) business
2020
Q2 Financial Results:
Revenue: $15.5 million
Operating Loss: $(1.0) million
YTD Q2 Financial Results:
Revenue: $37.3 million
Operating Loss: $(3.6) million
Cash and Cash Equivalents: $22.8 million
Expanding business development team
Clinical Trials Materials services operational June 2020
3
Gainesville CDMO Facilities
Gould Campus - Commercial and Solid Oral Dose Production
• 95,000 ft2 cGMP manufacturing facility
Chestnut Facility
24,000 ft2 Leased through 2025, with extension optionality
Specializing in:
Process Development and Formulation
High Potency Production
Analytical Services
Clinical Packaging and Logistics
4
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Recro Pharma Inc. published this content on 22 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 September 2020 11:09:04 UTC
Societal CDMO, Inc. is a bi-coastal contract development and manufacturing organization (CDMO). The Company is engaged in spanning pre-investigational new drug development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a primary focus in the area of small molecules. It is a CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The Company's key products include Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM, Verapamil SR and Donnatal liquids and tablets. Its manufacturing and development capabilities include product development from formulation through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms, with specialization in modified release technologies and facilities to handle potent compounds and controlled substances.
SOCIETAL CDMO, INC. 
